MetaCap

Atea Pharmaceuticals (AVIR) vs MapLight Therapeutics (MPLT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atea Pharmaceuticals (AVIR) has outperformed MapLight Therapeutics (MPLT) over the past year, gaining 33.3% versus a loss of 57.5%. MapLight Therapeutics is the larger company by market cap ($330.1 million vs $318.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVIR+33.33%MPLT-57.54%
+197%+63%-70%
Nov 21, 20251 yearNov 20, 2026
AVIR+21.85%MPLT-64.89%
+142%+34%-75%
Oct 27, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVIR versus MPLT key metrics
MetricAVIRMPLT
Share price$3.96$5.94
Market cap$318.00M$330.12M
1-day change+0.76%-7.48%
YTD return+10.92%-66.18%
1-year return+33.33%-57.54%
5-year return-51.35%—
EPS (TTM)$-1.95$-6.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-158.35M$-161.15M
52-week high$6.45$40.43
52-week low$2.96$5.93
Distance from 52-week high-38.60%-85.31%
Analyst consensusbuystrong_buy
Avg. price target upside+127.27%+340.24%
Average volume290.60K458.71K
Shares outstanding80.30M52.85M
Employees55133
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AVIR has outperformed MPLT by 90.9 percentage points over the past year.

About Atea Pharmaceuticals

AVIR stock →

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About MapLight Therapeutics

MPLT stock →

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees

AVIR vs MPLT FAQ

Which is bigger, Atea Pharmaceuticals or MapLight Therapeutics?

MapLight Therapeutics (MPLT) is larger, with a market capitalization of $330.12M compared with $318.00M for Atea Pharmaceuticals (AVIR).

Which stock has performed better over the past year, AVIR or MPLT?

AVIR returned +33.33% over the past 12 months, compared with -57.54% for MPLT (price return, excluding dividends). Past performance does not predict future results.

Are Atea Pharmaceuticals and MapLight Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons